Zapping prostate tumors with extra precision: new trial aims for fewer side effects

NCT ID NCT07644598

Recruiting now Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This phase II trial tests a new radiation technique for low to intermediate risk prostate cancer. It uses an MRI-guided 'microboost' to deliver a higher dose to the tumor while lowering the dose to the rest of the prostate. The goal is to see if this approach is safe and causes fewer urinary or bowel side effects. About 58 participants will receive treatment over two weeks and be followed for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (SBRT with microboost)
What this could lead to: If successful, this could offer a more precise, shorter radiation treatment for low to intermediate risk prostate cancer with fewer side effects.
What could go wrong: This is a small, early-phase safety trial (58 people). It may not prove effectiveness, and there is still a risk of urinary or bowel side effects from radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALIZED PROSTATE CARCINOMA PROSTATE CANCER

Contacts and locations

Locations

Lombardi Comprehensive Cancer Center, Georgetown University
RECRUITING

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.